ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial
ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial
ImmunityBio has struck a royalty deal with Oberland Capital, potentially adding $320 million to its coffers. The biotech is shoring up its cash reserves, while banking on FDA approval this spring for its bladder cancer drug.
ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference
First Data for Immunity’s Cytokine-Enriched NK Cells in Small Cell Lung Cancer
FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date
ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ